NCT05849766View on ClinicalTrials.gov

Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction

PHASE3CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

April 27, 2023

Primary Completion Date

May 1, 2024

Study Completion Date

September 1, 2024

Conditions

Dilated Cardiomyopathy

Interventions

DRUG

Dapagliflozin Farxiga®

Dapagliflozin 10 mg once daily

DRUG

Ramipril Tritace®, Carvedilol Carvid®,and Spironolactone Aldactone®

Ramipril 10 mg once daily, carvedilol 6.25 mg twice daily and spironolactone 25 once daily

Trial Locations (1)

Unknown

Beni-suef University, Banī Suwayf

All Listed Sponsors

collaborator

National Heart Institute, Egypt

OTHER_GOV

collaborator

University of Florida

OTHER

lead

October 6 University

OTHER

NCT05849766 - Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction | Biotech Hunter | Biotech Hunter